The biopharmaceutical company «Mercureid R&D» offers you information on the most important innovative research in cancer immunotherapy.
We have developed new molecules for immunotherapy new generation «smart PD-1/PD-L1/CD19/CD25/CD38 therapy».
The Nobel Prize in Physiology or Medicine 2018 was awarded jointly to James P. Allison and Tasuku Honjo "for their discovery of cancer therapy by inhibition of negative immune regulation".
For more than 100 years scientists attempted to engage the immune system in the fight against cancer. Until the seminal discoveries by the two laureates, progress into clinical development was modest. Checkpoint therapy has now revolutionized cancer treatment.
The field of immuno-oncology has made significant progress in the past decade. Cancer immunotherapies work by interfering with the inhibitory signals produced by tumors against specific constituents of the immune system. Because such inhibitory signals are mediated by "immune checkpoint" cell-surface molecules, the first generation of cancer immunotherapies are known as checkpoint inhibitors.
While checkpoint inhibitors have produced significant benefit for some patients, a large segment of patients fail to benefit from these therapies (very expensive, limited effectiveness, side effects, action on only 1 or 2 target proteins, etc.)
We have created molecules without the disadvantages of "immune checkpoint inhibitors" of the first generation
The stereochemical properties of the MSC-428 molecules make it possible to act on several target proteins that are crucial for the antitumor response of the organism:
Thus, «MSC-428» targeted for 4 target proteins, such as: PD-1 / PD-L1, CD19, CD25, CD38.
It should be noted that their activity recovery is largely predetermined by the normalization of other surface antigens of lymphocytes, such as: CD3, CD4, CD8, CD16, CD45, CD95, phagocyte system, immunoglobulin class A, M, G.
We used a fundamentally new approach that provides new opportunities for cancer therapy and prevention.
The unique pharmacochemical properties of the chelate nanocomplex MSC-428 provide an opportunity for multi-purpose therapy directed against several target proteins: PD-1 / PD-L1, CD19, CD25, CD38.
Thus, we overcome the shortcoming of traditional therapy with monoclonal antibodies. Because the effectiveness of mAb depends on the degree of affinity of the drug-antibodies to a specific protein receptor (PD-1, PD-L1 or CTLA-4 etc.).